Výsledky vyhledávání - Àngels Arcusa

  • Zobrazuji výsledky 1 - 9 z 9
Upřesnit hledání
  1. 1
    Clinical pharmacogenomic testing of KRAS, BRAF and EGFRmutations by high resolution melting analysis and ultra-deep pyrosequencing

    Clinical pharmacogenomic testing of KRAS, BRAF and EGFRmutations by high resolution melting analysis and ultra-deep pyrosequencing Autor Emma Borràs, Ismael Jurado, Imma Hernán, María José Gamundi, Miguel Dias, Isabel Casares San José Martí, Begoña Mañé, Àngels Arcusa, José A. G. Agúndez, Miguel Blanca, Miguel Carballo

    Vydáno 2011
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  2. 2
    Prescription refill, patient self-report and physician report in assessing adherence to oral endocrine therapy in early breast cancer patients: a retrospective cohort study in Catalonia, Spain

    Prescription refill, patient self-report and physician report in assessing adherence to oral endocrine therapy in early breast cancer patients: a retrospective cohort study in Cata... Autor Rebeca Font, Josep Alfons Espinàs, Miguel Gil‐Gil, Agustí Barnadas, B. Ojeda, Ignasi Tusquets, Miguel Ángel Seguí, Mireia Margelí Vila, Àngels Arcusa, A. Prat, Montse García, Josep M. Borràs

    Vydáno 2012
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  3. 3
    Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study

    Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study Autor Emilio Alba, Lourdes Calvo, Joan Albanell, Juan de la Haba-Rodríguez, Angels Arcusa Lanza, José Ignacio Chacón, Pedro Sánchez‐Rovira, Arrate Plazaola, José Antonio López García‐Asenjo, B. Bermejo, Eva Carrasco, Aña Lluch

    Vydáno 2012
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  4. 4
    Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Español de Investigación en Cáncer de Ovario) study

    Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Español de Investigación en Cá... Autor Antonio González-Martı́n, E. Calvo, Isabel Bover, María Jesús Rubio, Àngels Arcusa, Antonio Casado, B. Ojeda, Carmen Balañá, E Hortelano Martínez, Ana Herrero, Beatriz Pardo, Encarna Adrover, Juli Rifà, María José Godes, A Moyano, Andrés Cervantes

    Vydáno 2005
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  5. 5
    Epirubicin–cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: randomized phase III trial in postmenopausal node-positive breast cancer patients. A GEICAM 9401 study

    Epirubicin–cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: randomized phase III trial in postmenopausal node-positive breast ca... Autor Cesar Pico, Miguel Martín, Carlos Jara, Agustí Barnadas, A. Pelegrí, A. Balil, Carlos Camps, Alessandra Frau, Álvaro Rodríguez-Lescure, José Manuel López-Vega, Juan de la Haba-Rodríguez, A. Trés, Ivonne Álvarez, Emilio Alba, Àngels Arcusa, A. Oltra, N. Batista, T. Checa, R. Pérez-Carrión, Jordi Curto

    Vydáno 2003
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  6. 6
    Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen

    Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophos... Autor Miguel Martín, Aña Lluch, Miguel Ángel Seguí, A. Ruíz, Manuel Ramos, Encarna Adrover, Álvaro Rodríguez-Lescure, Regina Große, Lourdes Calvo, Concepción Fernández‐Chacón, Montserrat Roset, A. Antón, Dolores Isla, Purificación Martínez del Prado, L. Iglesias, J. Załuski, Àngels Arcusa, José Manuel López-Vega, Montserrat Muñoz, J. R. Mel

    Vydáno 2006
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  7. 7
    A PAM50-Based Chemoendocrine Score for Hormone Receptor–Positive Breast Cancer with an Intermediate Risk of Relapse

    A PAM50-Based Chemoendocrine Score for Hormone Receptor–Positive Breast Cancer with an Intermediate Risk of Relapse Autor Aleix Prat, Aña Lluch, Arran Turnbull, Anita K. Dunbier, Lourdes Calvo, Joan Albanell, Juan de la Haba-Rodríguez, Àngels Arcusa, José Ignacio Chacón, Pedro Sánchez‐Rovira, Arrate Plazaola, Montserrat Muñoz, Laia Paré, Joel S. Parker, Nuria Ribelles, Begoña Jiménez, Abdul Aziz Bin Aiderus, Rosalía Caballero, Bárbara Adamo, Mitch Dowsett, Eva Carrasco, Miguel Martín, J. Michael Dixon, Charles M. Perou, Emilio Alba

    Vydáno 2016
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  8. 8
    Adjuvant Docetaxel for High-Risk, Node-Negative Breast Cancer

    Adjuvant Docetaxel for High-Risk, Node-Negative Breast Cancer Autor Miguel Martín, Miguel Ángel Seguí, Antonio Antón, Amparo Ruı́z, Manuel Ramos, Encarna Adrover, Ignacio Aranda, Álvaro Rodríguez-Lescure, Regina Große, Lourdes Calvo, Agustí Barnadas, Dolores Isla, P. Martínez Del Prado, Manuel Ruíz Borrego, J. Załuski, Àngels Arcusa, Montserrat Muñoz, José Manuel López Vega, J. R. Mel, Blanca Munárriz, Cristina Llorca, Carlos Jara, Emilio Alba, Jesús Florián, Junfang Li, José Antonio López García‐Asenjo, Amparo Sáez, María Rios, Sergio Almenar, Gloria Peiró, Aña Lluch

    Vydáno 2010
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  9. 9
    Predicting response and survival in chemotherapy-treated triple-negative breast cancer

    Predicting response and survival in chemotherapy-treated triple-negative breast cancer Autor Aleix Prat, Aña Lluch, Joan Albanell, William T. Barry, Cheng Fan, José Ignacio Chacón, Joel S. Parker, Lourdes Calvo, Arrate Plazaola, Àngels Arcusa, Miguel Ángel Seguí, Octavio Burgués, Nuria Ribelles, Álvaro Rodríguez-Lescure, Ángel Guerrero, Manuel Ruíz‐Borrego, B. Munárriz, José Antonio López, Bárbara Adamo, Maggie C.U. Cheang, Yingying Li, Zhiyuan Hu, Margaret L. Gulley, María Vidal, Brandelyn N. Pitcher, M C Liu, Marc L. Citron, Matthew J. Ellis, Elaine R. Mardis, Tammi L. Vickery, Clifford A. Hudis, Eric P. Winer, Lisa A. Carey, Rosalía Caballero, Eva Carrasco, Miguel Martín, Charles M. Perou, Emilio Alba

    Vydáno 2014
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:

Vyhledávací nástroje: